Brain

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu...

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors

KELOWNA, BC, Jan. 16, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a...

Children’s Brain Tumor Network to Empower National Expansion of Pediatric Data Sharing Through ARPA-H Pediatric Care eXpansion (PCX)

CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's...

Children’s Brain Tumor Network to Empower National Expansion of Pediatric Data Sharing Through ARPA-H Pediatric Care eXpansion (PCX)

CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's...

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

error: Content is protected !!